Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs Phenprocoumon for Left Atrial Thrombus
NCT02591225Phase 4Unknown
- Sponsor
- Ulm University
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) and left atrial thrombosis (2 arms), sponsored by Ulm University. Primary endpoint: Left atrial thrombus resolution at 12 months. Status: unknown.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)left atrial thrombosis
Beyond the preview
Go deeper on NCT02591225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591225.